

Pfizer Withdraws EUA Application for COVID Shot in India After Regulator Asks for Independent Safety Study

By [Rishma Parpia](#)

Global Research, March 02, 2022

[The Vaccine Reaction](#) 22 February 2022

Region: [Asia](#)

Theme: [Science and Medicine](#)

All Global Research articles can be read in 51 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version).

To receive Global Research’s Daily Newsletter (selected articles), [click here](#).

Visit and follow us on Instagram at [@globalresearch_crg](#) and Twitter at [@crglobalization](#).

Pfizer, Inc. has withdrawn its emergency use authorization (EUA) application for its experimental BNT162b2 (also known as “Comirnaty”) messenger RNA (mRNA) COVID-19 biologic (developed in collaboration with Germany’s BioNTech) in India.¹

Pfizer was the first pharmaceutical company to apply for an EUA to distribute a COVID biologic in India in 2021. However, India’s regulatory agency approved two other COVID vaccines that are more cost effective: AstraZeneca/Oxford University’s experimental AZD1222 vaccine and the locally-manufactured BBV152 (“Covaxin”) vaccine by Bharat Biotech.²

During Pfizer’s meeting with India’s drug regulatory agency, the Central Drugs Standard Control Organization (CDSCO), the pharmaceutical decided to withdraw its application after the regulator requested a local trial on the vaccine’s safety and immunogenicity specifically for Indians.³

After a meeting with Pfizer officials, CDSCO said, “After detailed deliberation, the committee has not recommended grant of permission for emergency use in the country at this stage.”⁴

Pfizer Refused to Conduct Local Safety Trial for Its COVID Biologic Before Being Denied EUA in India

In order for the CDSCO to grant Pfizer an EUA for BNT162b2, the drugmaker was required to conduct a local clinical trial in India to determine if the vaccine is safe and generates an adequate immune response in its citizens.⁵

Vinod K. Paul, head of India’s government panel on vaccine strategy said that all foreign developed vaccines have to undergo a “bridging trial” in India in order to receive approval.

A “bridging trial” is required to determine the immune response and safety record of the vaccine in population with a different genetic makeup than in Western nations.⁶

Pfizer applied for an exemption from India’s “bridging trial” requirement by citing that it has received EUA approvals in other countries based on clinical trials conducted in the United States and Germany. Although there are provisions under India’s law to waive the requirements of “bridging trials” in certain circumstances, India’s regulatory agency decided not to waive the requirement for BNT162b2.⁷

The CDSCO’s website states:

The firm presented its proposal for emergency use authorization of COVID19 mRNA Vaccine BNT162b before the committee. The committee noted that incidents of palsy, anaphylaxis and other SAE’s have been reported during post marketing and the causality of the events with the vaccine is being investigated. Further, the firm has not proposed any plan to generate safety and immunogenicity data in Indian population. After detailed deliberation, the committee has not recommended for grant of permission for emergency use in the country at this stage.⁸

Since BNT162b2 must be stored at a low temperature of minus 94 Fahrenheit, Indian Health Ministry officials said that the biologic is not the best option for the country given that it requires expensive freezers that are not readily available in India.⁹

Currently, a local pharmaceutical company in India known as Dr. Reddy’s Laboratories is conducting a “bridging trial” for Russia’s COVID vaccine called Sputnik Light (a component of Sputnik V) developed by Moscow’s Gamaleya Institute of Epidemiology and Microbiology, which is expected to be approved for EUA in India.¹⁰

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, @globalresearch_crg and Twitter at @crglobalization. Forward this article to your email lists. Crosspost on your blog site, internet forums, etc.

Notes

¹ CNBC. [Pfizer withdraws application for emergency use of its Covid-19 vaccine in India](#). Feb. 5, 2022.

² Ibid.

³ Ibid.

⁴ Deutsche Welle. [India: Pfizer withdraws COVID vaccine application for emergency use](#). Feb. 5, 2022.

⁵ Das K. [Pfizer drops India vaccine application after regulator seeks local trial](#). *Reuters* Feb. 5, 2022.

⁶ Deutsche Welle. [India: Pfizer withdraws COVID vaccine application for emergency use](#). Feb. 5, 2022.

⁷ Das K. [Pfizer drops India vaccine application after regulator seeks local trial](#). *Reuters* Feb. 5, 2022.

⁸ Central Drugs Standard Control Organization. [Recommendations of the SEC meeting to examine COVID-19 related proposal under accelerated approval process made in its 141st meeting held on 03.02.2021 at CDSCO, HQ New Delhi](#). Feb. 3, 2022.

⁹ Deutsche Welle. [India: Pfizer withdraws COVID vaccine application for emergency use](#). Feb. 5, 2022.

¹⁰ Das K. [Pfizer drops India vaccine application after regulator seeks local trial](#). *Reuters* Feb. 5, 2022.

Featured image is from TVR

The original source of this article is [The Vaccine Reaction](#)
Copyright © [Rishma Parpia](#), [The Vaccine Reaction](#), 2022

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Rishma Parpia](#)

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca
www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca